The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg).sub.l;(;Lys).sub.m;(His).sub.n;(Orn).sub.o;(Xaa).sub.x. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

Provided are a recombinant polynucleotide encoding a polypeptide including a reporter moiety, a substrate moiety, and a destabilization moiety, a host cell including the same, and use thereof to measure the level of a protease by using the recombinant polynucleotide.

Synthetic adenoviruses with liver detargeting mutations and expressing an adenovirus type 34 (Ad34) fiber protein, or a chimeric fiber protein with an Ad34 knob domain, are described. The synthetic adenoviruses traffic to sites of tumors. Use of the synthetic adenoviruses for delivering diagnostic or therapeutic transgenes to tumors are also described.

Provided herein are co-assembling peptides which may form particles (e.g., nanoparticles or granules) under stimulating conditions. Also provided herein are protein carrying particles (e.g., nanoparticles or granules). Further provided herein, are methods of making each of the co-assembling peptides and particles (e.g., nanoparticles or granules).

A luciferase that includes an amino acid sequence in which a mutation is introduced into an amino acid sequence of a luciferase derived from Luciora kuroiwae. The luciferase catalyzes a luminescence reaction that generates luminescence having the maximum luminescent wavelength of 570 nm to 610 nm. The luminescence has an intensity at least 10 times higher than that of luminescence generated in a luminescence reaction catalyzed by a luciferase derived from Rhagophthalmus ohbai.

Disclosed herein are fluff pulp compositions, absorbent articles comprising the fluff pulp compositions, and related methods. The fluff pulp compositions comprise a chemiluminescent system configured to produce visible light upon contact with an aqueous system. Representative absorbent articles include disposable diapers and adult incontinence products. Representative chemiluminescent systems include bioluminescent systems.

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

The disclosure comprises novel Coelenterazine compounds and methods of use, including a simple delivery device for the photoprotein to create effects by their luminous reaction upon contact with surfaces that contain calcium. Calcium is ubiquitous in and on most surfaces and in the environment; it is this unique property of calcium that makes this a novel use of the photoproteins for entertainment. A base coelenterazine structure is depicted below. ##STR00001##

The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.

The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.